A Dose of Precision

April 24, 2018

Article

Oracea® 40-mg Capsules are the only FDA-approved oral formulation to treat the inflammatory lesions of rosacea. Oracea® 40-mg Capsules are precisely formulated with a uniquely designed release system, providing an immediate and delayed, non-antibiotic dose for anti-inflammatory control throughout the day.

Oracea® 40-mg Capsules are the only FDA-approved oral formulation to treat the inflammatory lesions of rosacea.

Oracea® 40-mg Capsules are precisely formulated with a uniquely designed release system, providing an immediate and delayed, non-antibiotic dose for anti-inflammatory control throughout the day.

Related Videos

Botulinum toxin for rosacea

Related Content

Julie Harper, MD, to Present a Rosacea Research Roundup and Pearls

September 27th 2023

Oral Macrolides Demonstrate Efficacy in Aseptic Facial Granuloma

September 8th 2023

In Rosacea, Botulinum Toxin Requires Further Analysis of Long-Term Clinical Efficacy and Safety

August 23rd 2023

Skin Responses Differ Among Patients With Seborrheic Dermatitis and Rosacea

Survey Finds That Laser Treatments Are Often Not Covered By Insurance

DFD-29 Achieves Phase 3 Co-Primary and All Secondary Endpoints for Papulopustular Rosacea Treatment

Julie Harper, MD, to Present a Rosacea Research Roundup and Pearls

September 27th 2023

Oral Macrolides Demonstrate Efficacy in Aseptic Facial Granuloma

September 8th 2023

In Rosacea, Botulinum Toxin Requires Further Analysis of Long-Term Clinical Efficacy and Safety

August 23rd 2023

Skin Responses Differ Among Patients With Seborrheic Dermatitis and Rosacea

Survey Finds That Laser Treatments Are Often Not Covered By Insurance

DFD-29 Achieves Phase 3 Co-Primary and All Secondary Endpoints for Papulopustular Rosacea Treatment

Julie Harper, MD, to Present a Rosacea Research Roundup and Pearls

September 27th 2023

Oral Macrolides Demonstrate Efficacy in Aseptic Facial Granuloma

September 8th 2023

In Rosacea, Botulinum Toxin Requires Further Analysis of Long-Term Clinical Efficacy and Safety

August 23rd 2023

Skin Responses Differ Among Patients With Seborrheic Dermatitis and Rosacea

Survey Finds That Laser Treatments Are Often Not Covered By Insurance

DFD-29 Achieves Phase 3 Co-Primary and All Secondary Endpoints for Papulopustular Rosacea Treatment

Related Content

Julie Harper, MD, to Present a Rosacea Research Roundup and Pearls

Julie Harper, MD, to Present a Rosacea Research Roundup and Pearls

Oral Macrolides Demonstrate Efficacy in Aseptic Facial Granuloma

Oral Macrolides Demonstrate Efficacy in Aseptic Facial Granuloma

In Rosacea, Botulinum Toxin Requires Further Analysis of Long-Term Clinical Efficacy and Safety

In Rosacea, Botulinum Toxin Requires Further Analysis of Long-Term Clinical Efficacy and Safety

Skin Responses Differ Among Patients With Seborrheic Dermatitis and Rosacea

Skin Responses Differ Among Patients With Seborrheic Dermatitis and Rosacea

Survey Finds That Laser Treatments Are Often Not Covered By Insurance

Survey Finds That Laser Treatments Are Often Not Covered By Insurance

DFD-29 Achieves Phase 3 Co-Primary and All Secondary Endpoints for Papulopustular Rosacea Treatment

DFD-29 Achieves Phase 3 Co-Primary and All Secondary Endpoints for Papulopustular Rosacea Treatment

Do Not Sell My Information

Terms and Conditions

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.